

In the Specification:

Page 1, after the title, please insert the following new paragraph:

This application is a continuation of U.S. Application No. 10/084,488, filed February 28, 2002, which is a continuation of U.S. Application No. 09/623,725, filed November 20, 2000 (abandoned), both of which are hereby incorporated by reference. U.S. Application No. 09/623,725 is the National Stage of International Application No. PCT/US99/05021, filed March 10, 1999; said International Application No. PCT/US99/05021 is a continuation-in-part of U.S. Application No. 09/042,105, filed March 13, 1998 (now U.S. Patent No. 6,040,157, issued March 21, 2000) and is a continuation-in-part of U.S. Application No. 09/107,997, filed June 30, 1998; said U.S. Application No. 09/042,105 is a continuation-in-part of U.S. Application No. 08/999,811, filed December 24, 1997 (now U.S. Patent No. 5,932,540, issued August 3, 1999), which is a continuation-in-part of U.S. Application No. 08/465,968, filed June 6, 1995 (now U.S. Patent No. 6,608,182, issued August 19, 2003), and a continuation-in-part of U.S. Application No. 08/207,550, filed March 8, 1994 (now abandoned).

At page 6:

Please replace the paragraph spanning lines 8-9 with the following paragraph:

~~Figure 14 depicts~~ Figures 14A-B depict expression of VEGF-2 mRNA in human fetal and adult tissues.

Please replace the paragraph at line 12 with the following paragraph:

~~Figure 16 depicts~~ Figures 16A-B depict transient expression of VEGF-2 protein in COS-7 cells.

Please replace the paragraph spanning lines 19-20 with the following paragraph:

~~Figure 20 depicts~~ Figures 20A-B depict inhibition of PDGF-induced vascular (human aortic) smooth muscle cell proliferation.

Please replace the paragraph spanning lines 29-32 with the following paragraph:

~~Figure 25 depicts~~ Figures 25A-O depict restoration of certain parameters in the ischemic limb by VEGF-2 protein (~~Figure 25, top panels~~) (Figures 25A, D, E, J and M) and naked expression plasmid (~~Figure 25, middle panels~~) (Figures 25B, F, G, K and N): BP ratio (~~Figure 25a~~) (Figure 25C); Blood Flow and Flow Reserve (~~Figure 25b~~) (Figures 25H and I); Angiographic Score (~~Figure 25e~~) (Figure 25L); Capillary density (~~Figure 25d~~) (Figure 25O).

At page 105:

Please replace the paragraph spanning lines 8-13 with the following paragraph:

Expression of VEGF-2 mRNA is abundant in vascular smooth muscle and several highly vascularized tissues. VEGF-2 is expressed at significantly higher levels in tissues associated with hematopoietic or angiogenic activities, i.e. fetal kidney, fetal lung, bone marrow, placental, spleen and lung tissue. The expression level of VEGF-2 is low in adult kidney, fetal liver, adult liver, testes; and is almost undetectable in fetal brain, and adult brain (See ~~Figure 14~~ Figures 14A-B).

At page 115:

Please replace the paragraph spanning lines 13-20 with the following paragraph:

As shown in ~~Figure 16, cells~~ Figures 16A-B, cells transfected with pcDNA 1 VEGF-2HA secreted a 56 kd and a 30 kd protein. The 56 kd protein, but not the 30 kd protein, could also be detected in the cell lysate but is not detected in controls. This suggests the 30 kd protein is likely to result from cleavage of the 56 kd protein. Since the HA-tag is on the C-terminus of VEGF-2, the 30 kd protein must represent the C-terminal portion of the cleaved protein, whereas the N-terminal portion of the cleaved protein would not be detected by immunoprecipitation. These data indicate that VEGF-2 protein expressed in mammalian cells is secreted and processed.

At page 117:

Please replace the paragraph spanning lines 11-12 with the following paragraph:

VEGF-2 has an inhibitory effect on proliferation of vascular smooth muscle cells induced by PDGF, but not by Fetal Bovine Serum (FBS) (~~Figure 20~~ Figures 20A-B).

At pages 122-123:

Please replace the paragraphs at page 122, line 16 through page 123, line 7 with the following paragraphs:

Both VEGF-2 protein (~~Figure 25, top panels~~) (Figures 25A, D, E, J and M) and naked expression plasmid (~~Figure 25, middle panels~~) (Figures 25B, F, G, K and N) were able to restore the following parameters in the ischemic limb. Restoration of blood flow, angiographic score seem to be slightly more by administration of 500 mg plasmid compared with by 500 mg protein (~~Figure 25, bottom panels~~) ~~The~~ (Figures 25C, H, I, L and O). ~~The~~ extent of the restoration is comparable with that by VEGF in separate experiments (data not shown). A vessel dilator was not able to achieve the same effect, suggesting that the blood flow restoration is not simply due to a vascular dilation effect.

a. BP Ratio (~~Figure 25a~~) (Figures 25A-C)

The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb.

2. Blood Flow and Flow Reserve (~~Figure 25b~~) (Figures 25D-I)

Resting FL: the blood flow during un-dilated condition

Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount)

Flow Reserve is reflected by the ratio of max FL: resting FL.

3. Angiographic Score (~~Figure 25e~~) (Figures 25J, K and L)

This is measured by the angiogram of collateral vessels. A score was determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh.

4. Capillary density (~~Figure 25d~~) (Figures 25M, N and O)

The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

Please delete pages 145-146 and renumber the Claim pages accordingly.